medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2003, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2003; 2 (4)


New therapies on the horizon for hepatitis C

Sookoian SC

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 164-170
Archivo PDF: 75.58 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Alter MJ. Epidemiology of Hepatitis C. Hepatology 1997; 26(Suppl 1): 62S-65S.

  2. Penin F. Structural biology of hepatitis C virus. Clin Liver Dis 2003; 7(1): 1-21.

  3. Cho PW, Westaway EG. Replication strategy of Kunjin virus: evidence for recycling role of replicative form RNA as template in semi conservative and asymmetric replication. Virology 1985; 140: 68-79.

  4. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003; 100(12): 7271-6.

  5. Lozach PY, Lortat-Jacob H, de Lacroix de Lavalette A, Staropoli I, Foung S, Amara A, Houles C, Fieschi F, Schwartz O, Virelizier JL, Arenzana-Seisdedos F, Altmeyer R. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem 2003; 30; 278(22): 20358-66.

  6. Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T, Olson WC. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci USA 2003; 15; 100(8): 4498-503.

  7. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, et al. Crystal structure of hepatitis virus NS3 proteinase domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 331-355.

  8. Barbato G, Cicero DO, Nardi MC, Steinkuhler C, Cortese R, De Francesco R, Bazzo R. The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein derives new insights into its activation and catalytic mechanisms. J Mol Biol 1999;289:371-384.

  9. Yao N, Hesson T, Cable M, Hong Z, Kwong AD, Le HV, Weber PC. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997; 4(6): 463-7.

  10. Zhang X. Inhibitors of hepatitis C: a review of the recent patent literature. I Drugs 2002; 5: 154-158.

  11. Randall G, Grakoui A, Rice ChM. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs . Proc Natl Acad Sci USA 2003, 7; 100(1): 235-40.

  12. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, Yi L, Kurosaki M, Taira K, Watanabe M, Mizusawa H. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 2003; 4(6): 602-8.

  13. Vidalin O, Major ME, Rayner B, Imbach JL, Trepo C, Inchauspe G. In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides. Antimicrobial Agents and Chemotherapy 1996; 40: 2337-2344.

  14. Hanecak R, Brown-Driver V, Foz MC, Azad RF, Furusako S, Nozaki C, Ford C, et al. Antisense oligonucleotide inhibition of hepatitis C virus gene expression and transformed hepatocytes. J Virol 1996; 70: 5203-5212.

  15. Hanecak R, Brown-Driver V, Fox MC, Azad RF, Furusako S, Nozaki C, Ford C, Sasmor H, Anderson KP. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J Virol 1996; 70(8): 5203-12.

  16. McCaffrey AP, Meuse L, Karimi M, Contag CH, Kay MA. A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology 2003; 38(2): 503-8.

  17. Sakamoto N, Wu CH, Wu GY. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest 1996; 15,98(12): 2720-8.

  18. Macejak DG, Jensen KL, Jamison SF, Domenico K, Roberts EC, Chaudhary N, von Carlowitz I, Bellon L, Tong MJ, Conrad A, Pavco PA, Blatt LM. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology 2000; 31(3): 769-76.

  19. Cocquerel L, Quinn ER, Flint M, Hadlock KG, Foung SK, Levy S. Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody. J Virol 2003; 77(2): 1604-9.

  20. Dagan S, Eren R. Therapeutic antibodies against viral hepatitis. Curr Opin Mol Ther 2003; 5(2): 148-55.

  21. Krawczynski K, Fattom A, Culver D. Passive transfer of Anti-HCV in chronic and acute HCV infections in chimpanzees-trials of experimental immune treatment. Hepatology 1999; 30: 423A.

  22. Houghton M. Strategies and Prospects for vaccination against the Hepatitis C viruses. Curr Top Microbiol Immunol 2000; 242: 327-329.

  23. Ma X, Forns X, Gutierrez R, Mushahwar IK, Wu T, Payette PJ, Bukh J, Purcell RH, Davis HL. DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine 2002; 10; 20(27-28): 3263-71.

  24. Watson J. Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin. Curr Opin Investig Drugs 2002; (5): 680-3.




2020     |     www.medigraphic.com